Wisconsin Medical Cyclotron and Radiopharmacy

What Wisconsin Medical Cyclotron and Radiopharmacy does

Wisconsin Medical Cyclotron and Radiopharmacy operates a radiopharmaceutical CDMO/CMO platform under the PharmaLogic trade name, providing contract development, manufacturing, and distribution services for diagnostic and therapeutic radiopharmaceuticals. The company is headquartered in West Allis, Wisconsin, with a SPECT radiopharmacy and PET production site at that location and an additional PET radiopharmaceutical manufacturing facility opened in Atlanta, Georgia in April 2026. Its core technology stack centers on cyclotron-driven isotope production, PET radiopharmaceutical compounding, chemistry-manufacturing-controls (CMC) capabilities spanning clinical through commercial stages, and specialized actinium-225 (Ac-225) production for therapeutic applications.

The business is organized around four integrated service lines: CDMO Services supporting drug development from clinical through commercial launch; CMO Diagnostics for diagnostic radiopharmaceutical manufacturing; CMO Therapeutics for therapeutic radiopharmaceutical manufacturing; and Supply Chain & Radiopharmacy for distribution and radiopharmacy operations. Customer engagement is B2B and enterprise-oriented, targeting pharmaceutical sponsors developing radiopharmaceutical products who require specialized regulatory-compliant manufacturing infrastructure and short-lived isotope logistics. Pricing is quote-based and not publicly disclosed, consistent with custom contract manufacturing economics.

The company is privately held as PharmaLogic Holdings Corp., serves the US market with a Southeast regional emphasis, and is actively expanding its therapeutic isotope capabilities through partnerships such as the expanded manufacturing collaboration with Ratio Therapeutics supporting the Ac-225-labeled RTX-2358 program and FAP-targeted radiopharmaceutical clinical supply. Disclosed headcount of 11-50 is reported at the firmographic level but likely understates the production workforce across multiple facilities.

Name

Wisconsin Medical Cyclotron and Radiopharmacy

Legal name

PharmaLogic Holdings Corp.

Website

https://wimedcyclotron.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Wisconsin Medical Cyclotron and Radiopharmacy (PharmaLogic) is a US-based CDMO/CMO providing radiopharmaceutical development, manufacturing, and distribution services for pharmaceutical sponsors across diagnostic and therapeutic programs.

Ownership category

akta.pro rank

Product category

Radiopharmaceutical Manufacturing and Distribution Services

NAICS

Pharmaceutical and Medicine Manufacturing (3254), In-Vitro Diagnostic Substance Manufacturing (325413), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF)

akta.pro secondary industries

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB), Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD), Radionuclide Supply Chain & Logistics (Shielding/Transport/Distribution) (HLAIAGAH), Radiopharmacy Compounding & Dispensing (Hospital/Commercial) (HLAIAGAE)

Keywords

• Radiopharmaceutical manufacturing
• CDMO services
• PET radiopharmacy
• SPECT imaging services
• Nuclear medicine

Headquarters

HQ city

West Allis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. CDMO Services: Contract Development and Manufacturing Organization services for pharmaceutical sponsors requiring radiopharmaceutical development from clinical through commercial stages
2. CMO Diagnostics: Contract Manufacturing Organization services specifically for diagnostic radiopharmaceuticals
3. CMO Therapeutics: Contract Manufacturing Organization services for therapeutic radiopharmaceuticals including alpha-emitter therapies
4. Supply Chain & Radiopharmacy: Supply chain management and radiopharmacy distribution services

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Wisconsin Medical Cyclotron and Radiopharmacy is a SPECT radiopharmacy and PET centre that provides compounding and distribution services for radiopharmaceuticals. As part of PharmaLogic Holdings Corp., it operates as a CDMO/CMO producing diagnostic and therapeutic radiopharmaceuticals used in the detection and treatment of cancer and other diseases.

Product overview

PharmaLogic operates as a unified platform providing end-to-end radiopharmaceutical services. The portfolio consists of four integrated service offerings: CDMO Services (contract development and manufacturing for drug development from clinical through commercial stages), CMO Diagnostics (contract manufacturing for diagnostic radiopharmaceuticals), CMO Therapeutics (contract manufacturing for therapeutic radiopharmaceuticals), and Supply Chain & Radiopharmacy (distribution and radiopharmacy services). Together, these offerings enable pharmaceutical companies to advance products from clinical development to commercialization.

Differentiator

Problem solved

Functional benefit

Products and services

• SPECT Radiopharmacy Compounding and Distribution Services
• PET Centre Radiopharmacy Services
• Radiopharmaceutical CDMO/CMO Services

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Ratio TherapeuticscoreStrategic or Co-development Partner · 29 May 2026PharmaLogic and Ratio Therapeutics expanded their manufacturing collaboration to support clinical development of Ac-225 RTX-2358, an actinium-225 based therapeutic radiopharmaceutical. The partnership builds on a prior collaboration that successfully supplied the first cohort dosing for Ratio's Phase 1/2 study of a novel FAP-targeted radiopharmaceutical in late-stage aggressive sarcomas.

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• Cardinal Health Radiopharmaceutical Distribution: Cardinal Health operates one of the largest nuclear pharmacy networks in the U.S. (Nuclear Pharmacy Services), distributing radiopharmaceuticals to hospitals and clinics. Overlaps with PharmaLogic's Supply Chain & Radiopharmacy offering at the distribution and dispensing layer.
• Lantheus Holdings: Lantheus is a vertically integrated radiopharmaceutical company with proprietary diagnostic products (e.g., Pylarify) and a manufacturing footprint. Comparable as a broad incumbent operating across diagnostic and therapeutic radiopharma manufacturing and distribution.
• GE HealthCare (Radiopharmaceuticals): GE HealthCare has a radiopharmaceutical manufacturing and distribution business (formerly GE Healthcare's Pharmaceutical Diagnostics) producing PET tracers and contrast media. A broad incumbent competing in the same radiopharma manufacturing and supply chain space.
• Bayer (Radiology / Curium JV legacy): Bayer historically had a large radiopharma business (sold into the Curium JV) and continues to participate in radioligand therapy through Nubeqa and other programs. Comparable as a broad incumbent with prior radiopharma manufacturing scale.

Emerging players

• Telix Pharmaceuticals: Telix develops and manufactures therapeutic and diagnostic radiopharmaceuticals (e.g., Illuccix) and contracts with CDMOs for scale-up. Comparable as a sponsor that also builds internal manufacturing capability, intersecting with PharmaLogic's CDMO/CMO model.
• Avid Radiopharmaceuticals (Eli Lilly): Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly, develops and manufactures PET imaging agents (e.g., Amyvid, Tauvid). Comparable as a sponsor with integrated diagnostic radiopharma manufacturing capability overlapping with PharmaLogic's CMO Diagnostics line.
• SOFIE Biosciences: SOFIE manufactures and distributes radiopharmaceuticals (FAPI, PSMA, and other diagnostic and therapeutic tracers) via a network of radiopharmacies. Comparable as an emerging player with overlapping diagnostic and therapeutic radiopharma manufacturing and distribution capabilities.
• Nucleus RadioPharma: Nucleus RadioPharma is a venture-backed CDMO focused on therapeutic radiopharmaceuticals, particularly actinium-225 (Ac-225) and other alpha-emitters. Directly comparable to PharmaLogic's therapeutic CMO and Ac-225 capabilities.

Direct peers

• Curium Pharma: Curium is one of the largest global radiopharmaceutical CDMOs and diagnostic manufacturers, operating PET and SPECT production networks. It directly competes with PharmaLogic across CDMO, CMO diagnostics, and nuclear medicine distribution.
• PETNET Solutions (Siemens Healthineers): PETNET operates the largest U.S. PET radiopharmacy distribution network and provides FDG and other PET tracer manufacturing. Directly comparable to PharmaLogic's Supply Chain & Radiopharmacy and CMO Diagnostics offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pharmalogic-holdings-corp

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wisconsin Medical Cyclotron and Radiopharmacy